PCAS: 2020 annual results
25 Febbraio 2021 - 5:45PM
PCAS: 2020 annual results
Ecully, February 25, 2021
2020 ANNUAL RESULTS
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its 2020 results.
|
in millions of euros |
|
2019 |
|
2020 |
|
| |
|
|
| |
|
|
|
|
|
|
|
Net sales |
|
200.9 |
|
194.1 |
|
| |
|
|
|
|
|
|
|
EBITDA (*) |
|
16.3 |
|
10.7 |
|
| |
EBITDA
margin |
|
8.1% |
|
5.5% |
|
| |
|
|
|
|
|
|
|
Current operating income (*) |
|
-3.5 |
|
-10.8 |
|
| |
Current
operating income margin |
|
-1.8% |
|
-5.5% |
|
| |
|
|
|
|
|
|
|
Other operating income and expenses |
|
-5.2 |
|
-0.2 |
|
| |
|
|
|
|
|
|
|
Operating income |
|
-8.7 |
|
-11.0 |
|
| |
|
|
|
|
|
|
|
Financial result |
|
-2.1 |
|
-1.6 |
|
|
Taxes |
|
-2.9 |
|
-2.4 |
|
| |
|
|
|
|
|
|
|
Net result |
|
-13.7 |
|
-14.9 |
|
|
(*) of which research tax credit (CIR): 4.5 M€ in 2019 and 4.3 M€
in 2020 |
|
|
|
|
|
|
Audit procedures have been performed and auditor’s report is in
progress of being issued. |
|
|
Results
The PCAS Group has generated consolidated net
sales of €194.1 million in fiscal year 2020, a decrease of 3.4%
(-2.7% at constant exchange rates) compared to fiscal year
2019.
The EBITDA amounted to €10.7 million, compared
to €16.3 million in 2019 (i.e. a margin of 5.5% versus 8.1% in
2019) and was primarily impacted negatively by the delay in
commissioning the new production unit at the Villeneuve-la-Garenne
site, the significant drop in demand for Lubricants linked to the
coronavirus crisis as well as, to a lesser extent, the resources
implemented to improve the industrial performance of several sites
in the Pharmaceutical Synthesis activity. Consequently, the current
operating income decreased to €-10.8 million, compared to €-3.5
million in 2019.
As a reminder, other operating income and
expenses included the costs associated with the reorganization of
the Longjumeau site for €3.8 million in 2019.
The financial result showed a loss of €1.6
million in 2020, compared to a loss of €2.1 million in 2019.
The PCAS Group's net result was a loss of €14.9
million in 2020, compared to a loss of €13.7 million in 2019.
The Group's net debt (including Net Current
Account credit balance with Seqens) totaled €133.4 million vs.
€97.7 million at December 31, 2019.
Outlook for the current
year
As mentioned in our previous press releases
since end-March 2020, the global health crisis relating to the
coronavirus is changing by the day, and there is still a gray area
surrounding its duration, its extent and its effects on companies'
production lines and consumption in general.
The potential impacts in the medium term remain
difficult to anticipate. This crisis calls for cautious measures.
Due to the exceptional circumstances, the Group has suspended its
financial targets and its strategic business objectives until the
situation becomes clearer.
Dividend
In view of the Group's financial performance in
2020, the Board of Directors will ask the next Annual General
Meeting to approve no dividend payment on 2020 results.
NEXT FINANCIAL DISCLOSURE:2020
Shareholder's Meeting, May 12, 2021, 10 a.m.
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With 10% of its net sales earmarked for R&D and a
large international footprint, PCAS is the preferred industrial
partner for market-leading major global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €194.1 million in 2020 and employs close to 1 100
people in six countries.
To find out more about PCAS: www.pcas.com
|
PCAS |
Newcap |
|
Pierre Luzeau / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier Financial
communication and Investor Relations |
|
Tel: +33 1 69 79 60 00 www.pcas.com |
Tel: +33 1 44 71 98 53pcas@newcap.eu |
- PCAS - Annual Results 2020_en-US
Grafico Azioni PCAS (EU:PCA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni PCAS (EU:PCA)
Storico
Da Apr 2023 a Apr 2024
